Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | AGXT | P21549 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13618121 | 0.83 | MAOB (0.46) | MAOBABCB1APPPDE2AMAPT | |
| SCHEMBL8264411 | 0.82 | MAOB (0.44) | MAOBABCB1APPPDE2AMAPT | |
| SCHEMBL91372 | 0.81 | MAOB (0.43) | MAOBABCB1APPPDE2AMAPT | |
| SCHEMBL78450 | 0.79 | MAOB (0.43) | MAOBABCB1APPPDE2AMAPT | |
| SCHEMBL21580746 | 0.79 | HTR7 (0.42) | MAOBHTR7ABCB1MAPTSMN1; SMN2 | |
| SCHEMBL8262885 | 0.78 | ENPP2 (0.47) | MAOBABCB1APPPDE2AENPP2 | |
| SCHEMBL9598308 | 0.78 | RAB9A (0.48) | MAOBHTR7 | |
| SCHEMBL5183 | 0.77 | HTR7 (0.51) | MAOBHTR7MAPT | |
| SCHEMBL29574709 | 0.77 | HTR7 (0.51) | MAOBHTR7MAPT | |
| SCHEMBL25930635 | 0.76 | MAOB (0.51) | MAOBHTR7MAPTSMN1; SMN2AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| EP-2177518-A1 | Organic compounds | Novartis AG (CH) | 2010-04-21 | — | — | EP | disclosed |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| WO-2006069788-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | REN, PAH, ACE | MAOB 624/4885HTR7 548/4885ABCB1 504/4885 |
| US-20110263560-A1 | Organic Compounds | REN, ACE, OTC | MAOB 63/4885HTR7 1671/4885ABCB1 398/4885 |
| US-20090312304-A1 | ORGANIC COMPOUNDS | REN, ACE, PIGO | MAOB 35/4885HTR7 1550/4885ABCB1 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.